Skeletal muscle dysfunction with advancing age
Clinical Science · 17.07.2024 · 138 (14) · 863-882
DOI: 10.1042/cs20231197 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Science, online erschienen am 12.07.2024. Verfasst von Pardeep Pabla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Metabolism, Ageing and Physiology (COMAP), School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, DE22 3DT, U.K. Hauptthemen laut MEDLINE: Muscle, Skeletal, Sarcopenia, Aging. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 250 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council (MRC).
Abstract (Originalsprache)
As a result of advances in medical treatments and associated policy over the last century, life expectancy has risen substantially and continues to increase globally. However, the disconnect between lifespan and ‘health span’ (the length of time spent in a healthy, disease-free state) has also increased, with skeletal muscle being a substantial contributor to this. Biological ageing is accompanied by declines in both skeletal muscle mass and function, termed sarcopenia. The mechanisms underpinning sarcopenia are multifactorial and are known to include marked alterations in muscle protein turnover and adaptations to the neural input to muscle. However, to date, the relative contribution of each factor remains largely unexplored. Specifically, muscle protein synthetic responses to key anabolic stimuli are blunted with advancing age, whilst alterations to neural components, spanning from the motor cortex and motoneuron excitability to the neuromuscular junction, may explain the greater magnitude of function losses when compared with mass. The consequences of these losses can be devastating for individuals, their support networks, and healthcare services; with clear detrimental impacts on both clinical (e.g., mortality, frailty, and post-treatment complications) and societal (e.g., independence maintenance) outcomes. Whether declines in muscle quantity and quality are an inevitable component of ageing remains to be completely understood. Nevertheless, strategies to mitigate these declines are of vital importance to improve the health span of older adults. This review aims to provide an overview of the declines in skeletal muscle mass and function with advancing age, describes the wide-ranging implications of these declines, and finally suggests strategies to mitigate them, including the merits of emerging pharmaceutical agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre of Metabolism, Ageing and Physiology (COMAP), School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, DE22 3DT, U.K.
- MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research (CMAR), U.K.
- NIHR Nottingham Biomedical Research Centre (BRC), U.K.
ORCID-Profile: Bethan E Phillips
Förderung
- Medical Research Council (MRC)
Zitieren
APA
Pabla, P., Jones, E. J., Piasecki, M., & Phillips, B. E. (2024). Skeletal muscle dysfunction with advancing age. Clinical Science, 138(14), 863-882. https://doi.org/10.1042/cs20231197
Vancouver
Pabla P, Jones EJ, Piasecki M, Phillips BE. Skeletal muscle dysfunction with advancing age. Clinical Science. 2024;138(14):863-882. doi:10.1042/cs20231197
BibTeX
@article{Pabla2024,
author = {Pabla, Pardeep and Jones, Eleanor J and Piasecki, Mathew and Phillips, Bethan E},
title = {Skeletal muscle dysfunction with advancing age},
journal = {Clinical Science},
year = {2024},
volume = {138},
number = {14},
pages = {863--882},
doi = {10.1042/cs20231197}
}
EUVIMED